Dr Sharon Cheetham

Sharon is a Director and cofounder of RenaSci Limited, (acquired by the Sygnature Group in 2018) a specialist provider of experimental and consultancy services in the therapeutic areas of metabolic and CNS disorders. She is a visiting Professor at the University of Nottingham and an external examiner at the University of Bath. Sharon started her scientific career as a Research Assistant at the Institute of Psychiatry, University of London working in the field of epilepsy with Professor Brian Meldrum. Then on to St George’s Hospital Medical School to study for her Ph.D.: ‘Neurotransmitters and their receptors in post-mortem brain from depressed suicide victims’ with Professor Roger Horton. She transitioned from academia to industry by joining Boots Pharmaceuticals in 1988. Boots became BASF Pharma where Sharon headed the team investigating CNS approaches to treat obesity and was involved in the registration of sibutramine in Europe and USA.